NDLI: Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.

Please wait, while we are loading the content...

Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.

Pattern of prophylaxis administration for chemotherapy-induced nausea and vomiting: an analysis of city-based health insurance data.

A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.

Difficulty in the management of pregnancy after vaginal radical trachelectomy.

Efficacy of carbon-ion radiotherapy and high-dose chemotherapy for patients with unresectable Ewing's sarcoma family of tumors.

Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.

Prognosis of gastric carcinoma patients aged 85 years or older who underwent surgery or who received best supportive care only.

Short-term functional and oncological outcomes of partial nephrectomy for renal cell carcinoma in patients with an anatomically or functionally solitary kidney: single-center experience.

Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.

Association between carotenoids and outcome of cervical intraepithelial neoplasia: a prospective cohort study.

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.

Lymphatic invasion identified with D2-40 immunostaining as a risk factor of nodal metastasis in T1 colorectal cancer.

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.

Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.

Prognostic significance of vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.

Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy.

Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.

Wide range and variation in minimally invasive surgery for renal malignancy in Japan: a population-based analysis.

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.

Current status of treatment strategy for elderly patients with gastric cancer.

Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.

Current chemotherapeutic approaches for hepatoblastoma.

Current therapeutic strategies for childhood hepatic malignant tumors.

Current therapeutic strategies for childhood hepatic tumors: surgical and interventional treatments for hepatoblastoma.

International pediatric liver cancer pathological classification: current trend.

Year: 2013 Volume: 18 Issue: 5

Year: 2013 Volume: 18 Issue: 4

Year: 2013 Volume: 18 Issue: 3

Year: 2013 Volume: 18 Issue: 2

Year: 2013 Volume: 18 Issue: 1

Year: 2012 Volume: 17

Year: 2011 Volume: 16

Year: 2010 Volume: 15

Year: 2009 Volume: 14

Year: 2000 Volume: 5

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Ohara, Tatsuru Kobayashi, Yoichi Yoshida, Ayako Yoshioka, Norihito Yahagi, Namiko Kondo, Haruhiro Tozawa, Akiko Kiguchi, Kazushige Suzuki, Nao
Description	Country affiliation: Japan Author Affiliation: Ohara T ( Department of Obstetrics and Gynecology, School of Medicine, St. Marianna University, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa, 216-8511, Japan.)
Abstract	BACKGROUND: The clinical activity of combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer was evaluated retrospectively. METHODS: Intravenous CPT-11 was given at 60 mg/m(2) (days 1, 8, 15), followed by NDP 80 mg/m(2) (day 1), every 4 weeks. RESULTS: According to the medical records, 29 cases have received this regimen since 2000. Median age was 57 years (range, 29-80), and performance status (PS) of the patients was 18 cases with PS 0, 10 cases with PS 1, and 1 case with PS 2, respectively. Clinical stage was as follows: 3 cases of stage Ib1, 2 cases of Ib2, 2 cases of IIa, 10 cases of IIb, 8 cases of IIIb, and 4 cases of IVb. There were 27 cases of squamous cell carcinoma and 2 cases of adenocarcinoma. Concerning hematological toxicity of grade 3 or more, neutropenia, leukopenia, and febrile neutropenia were observed in 79.3 %, 96.6 %, and 13.8 % of cases, respectively. For nonhematological toxicity, nausea, anorexia, joint pain, and confusion were observed in only 1 case, respectively, and as a result, in 7 cases chemotherapy was not completed. Among 26 cases with clinically evaluable lesions, there were 7 complete responses, 3 partial responses, 7 stable disease, and 9 progressive disease; the clinical response rate was 38.5 %. Median progression-free survival was 7 months (range, 0-38 months). CONCLUSION: The combination of CPT-11 and NDP seems to be active for patients with recurrent uterine cervical cancer.
File Format	HTM / HTML
ISSN	13419625
Issue Number	6
Volume Number	18
e-ISSN	14377772
Journal	International Journal of Clinical Oncology
Language	English
Publisher	Springer
Publisher Date	2013-12-01
Publisher Place	Japan
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Camptothecin Analogs & Derivatives Neoplasm Recurrence, Local Drug Therapy Organoplatinum Compounds Administration & Dosage Uterine Cervical Neoplasms Adult Aged Aged, 80 And Over Antineoplastic Combined Chemotherapy Protocols Adverse Effects Cisplatin Disease-free Survival Female Humans Middle Aged Pathology Neoplasm Staging Classification Journal Article
Content Type	Text
Resource Type	Article
Subject	Hematology Surgery Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A16 and UGT1A128 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.

Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.

Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.

A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.

The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.

Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.

Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.

Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.

Similar Documents

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.

Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.

Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.

A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.

The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.

Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.

Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.

Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity.

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer.

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A16 and UGT1A128 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.